Bio-Path Holdings to Present at the BIO CEO & Investor Conference
05 févr. 2018 16h01 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Appoints Paul Aubert to its Board of Directors
05 févr. 2018 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Third Quarter 2017 Financial Results
09 nov. 2017 16h01 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts
06 nov. 2017 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...